Research Article

Jing Liu, Die Liu, Haixiao Liang, Qi Sun, Yuanmei Chen, Fang Ye, Qi Zhang*

Association of placenta weight and morphology with term low birth weight: A case-control study

https://doi.org/10.1515/med-2025-1264 received June 27, 2025; accepted July 15, 2025

Abstract

Background and aim – Few studies identified the role of the placenta in birth weight. We aimed to explore the connection between placenta weight, morphology, and term low birth weight (TLBW).

Methods – This was a case—control study of neonates born at ≥37 weeks' gestation enrolled in a general hospital from January 2018 to November 2022. Cases (<2,500 g) identified via birth certificates or medical records were matched with controls on the basis of date of birth, gestational age, sex, and maternal age. A nomogram predictive model was constructed based on logistic regression, using placenta parameters and perinatal information.

Results - A total of 290 neonates (115 with diagnosed TLBW and 175 controls) were determined. There were no significant differences between the two groups concerning gestational age (265.5 \pm 5.4 vs 266.3 \pm 5.3 days, P = 0.1397), gender, and maternal age at delivery (32.0 \pm 3.5 vs 32.1 \pm 3.1 years, P = 0.867). The placenta weight (479.0 ± 80.1 vs 597.1 \pm 83.1 cm), length (16.3 \pm 2.1 vs 18.8 \pm 2.0 cm), width (14.3 \pm 2.1 vs 16.9 \pm 2.0 cm), and thickness (2.3 \pm 0.5 vs 2.4 \pm 0.4 cm) in the TLBW group were much lower than those in the control group (all P < 0.001). Univariate predictors of TLBW included smaller placental weight, length, width, thickness, volume, and surface area. When put into a multivariate model, placental weight (aOR for per 10 g increase: 0.89; 95% CI: 0.84-0.94) and width (aOR for per 1 cm increase: 0.69; 95% CI: 0.54-0.88) remained to be independent predictors even after controlling for relevant confounders. The odds of TLBW increased when placental weight was below the 50th percentile (aOR: 5.08, 95% CI: 2.59-9.95). Placental width below the 50th percentile was significantly associated with an increased risk of TLBW (aOR: 6.57, 95% CI: 2.73-15.82).

Conclusions – Placental weight and width were found to be associated with TLBW. Further studies focusing on placental function, histology, and pathophysiology are needed to better understand the underlying mechanisms influencing fetal growth and TLBW.

Keywords: placenta weight, placenta morphology, low birth weight, term birth

1 Introduction

Birth weight, an essential indicator of fetal growth, nutrition, and placenta function, is closely related to perinatal survival and later-life health. In 2015, an estimated 20.5 million babies worldwide were born with low birth weight (LBW, <2,500 g), accounting for 14.6% of all live births [1]. According to the gestational weeks, LBW is distinguished into three categories: preterm LBW, term LBW (TLBW), and postterm LBW. About 91% of LBW infants were born in low- and middle-income countries, and the majority was predominated by TLBW [2]. It was discovered that birth weight has a far greater effect on mortality rates than gestational age [3]. Moreover, LBW has become the second leading cause of perinatal death after preterm birth. Notably, TLBW weighing 1,500–2,500 g had a perinatal mortality rate that was 5-30 times that of normal birth weight infants [3]. Growing evidence suggests that LBW raises the risk of adult disease, especially coronary heart disease, hypertension, and chronic renal disease [4,5].

Factors that may affect fetal growth are manifold and can be divided into different categories: fetal, maternal, uterine-placental, and environmental factors. Additionally, it should be highlighted that TLBW is generally accompanied with intrauterine dystrophy due to abnormal placental circulation. The placenta performs crucial physiological tasks like transport, endocrine, metabolic, and immune functions, serving as a regulatory interface between the mother and the fetus [6,7]. Fetal growth and development are critically dependent on the placental transfer capacity of nutrients, waste products, and other solutes, which is determined by several key components, such as placental size, morphology,

^{*} Corresponding author: Qi Zhang, Department of Pediatrics, China-Japan Friendship Hospital, Beijing, China, e-mail: zhangqikeyan@163.com Jing Liu, Die Liu, Haixiao Liang, Qi Sun, Yuanmei Chen, Fang Ye: Department of Pediatrics, China-Japan Friendship Hospital, Beijing, China ORCID: Jing Liu 0000-0002-6427-3126; Qi Zhang 0000-0001-5803-2556

transporter abundance and activity, maternal supply ability, and uterine-placental blood flow [8–10]. Indeed, poor placentation, including structurally damaged, abnormal development, insufficiency, dysfunction, etc., is associated with adverse pregnancy outcomes such as miscarriage, pre-eclampsia, intrauterine growth restriction (IUGR), preterm birth, and abnormal birth weight [11–14]. Therefore, it is essential to understand how the placenta develops and functions in order to identify potential targets for preventative or therapeutic interventions to promote child—maternal health.

Studies have demonstrated that the placenta structure and appearance could quantify placenta function to some extent. A reduction in placental volume and surface area, as well as increased thickness, may be markers of placental insufficiency [15]. Additionally, aberrant placental shape may be related to reduced placental efficacy [16]. The associations between placenta morphological measurements and health consequences are also identified in the current literature. Placenta weight is proportional to birth weight to the 0.75 power in term infants [17]. Reduced placenta weight, smaller surface area, or increased placenta thickness-to-volume ratio are observed in fetuses with IUGR [18-20]. Small placental size and uteroplacental malperfusion are more common in term small for gestational age (SGA) than in term appropriate for gestational age (AGA) placentas [21].

Although changes in the absolute or relative placenta size or weight do not necessarily indicate changes in placental function, morphometric measurements of the placenta can provide additional insights into aspects of fetal health and pregnancy outcomes. We hypothesize that differences in placenta development affect placenta function, which in turn influences fetal development, and that variations in placenta morphology are associated with neonatal birth weight. Therefore, we conducted this casecontrol study in order to fully understand the role of placenta morphological changes in the development of TLBW. In this study, we measured a set of gross morphometric parameters of the placenta, including placental weight, thickness, and inner diameter, and evaluated whether these parameters differed between singleton TLBW infants and normal birth weight infants. We also performed univariate and multivariate logistic regression analysis and drew a nomogram.

2 Methods

2.1 Study design

This case—control study collected the dataset of 10,511 singletons live births delivered in a tertiary general hospital in Beijing from January 1, 2018 to November 1, 2022. We included newborns ≥37 weeks gestational age (GA) with




Figure 1: Flow chart of study sample selection.

birth weight (BW) <4,000 g. Cases were defined as BW <2,500 g and GA ≥37 weeks with a diagnosis TLBW. We matched each TLBW case with 1.5 term normal birth weight (TNBW) controls based on gestational age, sex, date of birth, and maternal age at childbirth. One infant was excluded due to congenital heart disease and two infants were not included because they either did not receive prenatal check-ups or received care elsewhere finally leaving a final study group of 115 TLBW cases and 175 TNBW controls (Figure 1). The hospital's Ethical Committee authorized this research. Parental informed consent was obtained in writing from each participant.

2.2 Newborn and maternal clinical data

The hospital's electronic medical record system was reviewed to obtain clinical information regarding both newborns and mothers. We collected neonatal characteristics, such as gender, gestational age, birth weight, gravidity, parity, length, and head circumference. Additionally, we gathered information about each newborn's mother, including her age at delivery, ethnicity, delivery and conception method, pre-pregnancy weight and height, gestational weight gain, maternal comorbidities, pre-existing chronic diseases, medication use during pregnancy, and any fetal appendage abnormalities. Gestational age was determined based on the last menstrual period, which was cross-checked for accuracy.

2.3 Placenta data

Measurements of placental morphological parameters were performed by trained professionals using standardized protocols. After the delivery of the placenta, fetal membranes were trimmed and the umbilical cord was removed within approximately 5 cm of insertion. The excess blood clots were washed away with normal saline, and any water stains on the surface of the placenta were wiped dry with gauze. The following were immediately measured: placental weight was measured using a standard scale with an accuracy of 1g; the placental length diameter was measured along the longest axis, and the width diameter was measured along the axis perpendicular to the longest axis; placental thickness was measured at the thickest point, with multiple measurements taken to minimize variability and the maximum value used for analysis. The difference in diameters was calculated as the length diameter minus the width diameter. Placenta surface area and volume are calculated according to the following formula: Surface area = $\pi/4^*$ length diameter* width diameter; Volumes = $4/3*\pi*$ length diameter/2* width diameter/2* thickness/2; Specific surface area (Sv) = Surface area/Volume [22-25].

The technicians responsible for weighing the placenta and those measuring the infant's birth weight were separate individuals who did not have access to each other's results, thereby ensuring that no measurement bias was introduced.

2.4 Statistical analyses

Mean and standard deviation (SD) were reported for continuous variables, while integers and proportions were used for categorical variables. Utilizing appropriate statistical analyses, such as the Chi-square test and the Mann–Whitney U-test, we analyzed the difference in characteristics between the TLBW and control groups. Medians and quartiles were calculated to describe the distribution of placental morphology measurements. Logistic regression analyses were carried out to examine the association of the placental morphology indices (placental weight, length, width, thickness, etc.) with TLBW. Considering the nonlinear association pattern, all the subjects enrolled were also divided into two groups according to the median of the placental morphology measurements. Univariate analysis was carried out first, followed by multivariate analysis incorporating variables with significant findings in univariate analysis. Collinearity among the variables in the multivariable model was examined using variance inflation factor (VIF), and significant collinearity variables (i.e., surface area and volume, VIF > 10) were excluded. Adjusted odds ratio (aOR) with a 95% confidence interval (CI) was estimated by adjusting for possible confounders, including gravidity, parity, maternal height, and maternal weight before delivery. A nomogram was constructed to predict TLBW probability based on our final adjusted multivariable model. A two-sided P < 0.05 was used to declare statistical significance. R software version 4.1.1 was used for all statistical analyses.

Informed consent: Parental informed consent was obtained in writing from each participant.

Ethical approval: This study was approved by the China-Japan Friendship Hospital ethics committee board (2023-KY-057). All methods were carried out in accordance with relevant guidelines and regulations.

3 Results

3.1 General characteristics

Tables 1 and 2 summarize the clinical features of the mothers and neonates enrolled in this study, respectively. The neonates' gestational age ($265.5 \pm 5.4 \text{ vs } 266.3 \pm 5.3 \text{ days}$, P = 0.1397), gender, ethnicity, maternal age ($32.0 \pm 3.5 \text{ vs } 32.1 \pm 3.1 \text{ years}$, P = 0.867), method of delivery, or conception showed no significant difference between TLBW cases and TNBW group. There was a large difference in birth weight between TLBW ($2327.0 \pm 161.2 \text{ g}$) and TNBW ($3081.3 \pm 311.0 \text{ g}$) infants, with associated differences in length and head circumference (Table 1).

We observed that both the maternal weight and weight before delivery were significantly lower in the TLBW group (P < 0.05), while gestational weight gain and pre-pregnancy body mass index (BMI) did not show significant differences between the two groups (Table 2). Pregnancy complications (such as premature rupture of membranes (PROM), preeclampsia, gestational diabetes mellitus [GDM], hypertension, anemia, uterine fibroids, and hypothyroidism), some maternal chronic disease before pregnancy (including hypothyroidism and Hashimoto thyroiditis), and medication use in pregnancy (for example, levothyroxine, aspirin, labetalol, and prednisone) did not significantly differ (P > 0.05). The TLBW group had a higher incidence of oligohydramnios, meconium-stained amniotic fluid, and umbilical cord twist (P < 0.05). However, no significant differences were seen between the two groups with regard to the incidence of umbilical cord around the neck or prolapse, velamentous or battledore placenta, placental abruption or adhesion, etc. (P > 0.05).

Table 1: Baseline characteristics of eligible neonates (n = 290)

Variables	TLBW group (<i>n</i> = 115)	TNBW group (<i>n</i> = 175)	P value
Gestational age (days), mean ± SD	265.5 ± 5.4	266.3 ± 5.3	0.1397
Sex, n (%)			0.431
Male	42 (36.5)	72 (41.1)	
Female	73 (63.5)	103 (58.9)	
Birth weight (g), mean ± SD	2327.0 ± 161.2	3081.3 ± 311.0	<0.0001
Gravidity, mean ± SD	1.5 ± 0.8	1.8 ± 1.0	0.0201
Parity, mean ± SD	1.1 ± 0.3	1.4 ± 0.5	< 0.0001
Length, mean ± SD	47.0 ± 1.6	49.8 ± 1.2	< 0.0001
Head circumference, mean ± SD	32.0 ± 1.3	33.5 ± 1.3	<0.0001

Table 2: Descriptive statistics of maternal information, amniotic fluid, umbilical cord, and placenta characteristics

mean ± SD ithnicity, n (%) Han 10' Others* 14 Delivery mode, n (%) Forceps delivery 5 (Spontaneous vaginal 40 Idelivery Caesarean section 70 Conception method, n (%) Spontaneously conceived 11C IVF-ET 5 (Maternal height, mean ± SD Gestational weight before 16 Idelivery, mean ± SD Gestational weight gain (kg), 10 Inean ± SD Pre-pregnancy BMI, 25 Inean ± SD Pre-pregnancy BMI, 25 Inean ± SD Pre-pregnancy BMI, 26 Inean ± SD Pre-pregnancy BMI, 27 Inean ± SD Pre-pregnancy BMI, 32 Inean ± SD Pre-pregnancy m (%) Inean ± SD Inea	0 ± 3.5 (87.8) (12.2) 4.3) (34.8) (60.9) (95.7) 4.3) .3 ± 5.3 6 ± 10.1	32.1 ± 3.1 162 (92.6) 13 (7.4) 5 (2.9) 82 (46.9) 88 (50.3) 167 (95.4) 8 (4.6) 163.1 ± 4.8 70.1 ± 9.1	0.867 0.174 0.108 0.928 0.003
nean ± SD Athnicity, n (%) Han 10' Others* 14 Delivery mode, n (%) Forceps delivery 5 (Spontaneous vaginal 40 Idelivery Caesarean section 70 Conception method, n (%) Spontaneously conceived 11C IVF-ET 5 (Maternal height, mean ± SD Atternal weight before 16 Idelivery, mean ± SD Atternal weight gain (kg), nean ± SD Atternal pregnancy BMI, 25 Atternal spontage 12 Atternal pregnancy n (%) Atternal anemia, n (%) 32 Atternal anemia, n (%) 32 Atternal chronic disease 16 Atternal c	(87.8) (12.2) 4.3) (34.8) (60.9) (95.7) 4.3) .3 ± 5.3 6 ± 10.1	162 (92.6) 13 (7.4) 5 (2.9) 82 (46.9) 88 (50.3) 167 (95.4) 8 (4.6) 163.1 ± 4.8	0.174 0.108 0.928
thincity, n (%) Han 10′ Others* 14 Delivery mode, n (%) Forceps delivery 5 (Spontaneous vaginal 40 Idelivery Caesarean section 70 Conception method, n (%) Spontaneously conceived 110′ IVF-ET 5 (Maternal height, mean ± SD 6 Idelivery, mean ± SD 7 Idestational weight before 16 Idelivery, mean ± SD 7 Idestational weight gain (kg), 10. Inean ± SD 7 Idestational hypertension, 12 Idestational hypertension, 13 Idestational anemia, n (%) Idestational anemia, n (%) Idestational anemia, n (%) Idestational hypertension, 16 Idestational anemia, n (%) Idestational anemia, n (%) Idestational anemia, n (%) Idestational anemia, n (%) Idestational chronic disease Idestational chronic di	(12.2) 4.3) (34.8) (60.9) (95.7) 4.3) .3 ± 5.3 6 ± 10.1	13 (7.4) 5 (2.9) 82 (46.9) 88 (50.3) 167 (95.4) 8 (4.6) 163.1 ± 4.8	0.108
Han 100 Others* 14 Delivery mode, n (%) Forceps delivery 5 (Spontaneous vaginal 40 Delivery Caesarean section 70 Conception method, n (%) Spontaneously conceived 110 IVF-ET 5 (Maternal height, mean ± SD 6 Destational weight before 16 Delivery, mean ± SD 7 Destational weight gain (kg), 10 Destational weight gain (kg), 10 Destational hypertension, 10 Destational hypertension, 10 Destational hypertension, 10 Destational anemia, n (%) 12 Destational anemia, n (%) 13 Destational anemia, n (%) 14 Destational hypertension, 16 Destational anemia, n (%) 15 Destational anemia, n (%) 16 Destational anemia, n (%) 17 Destational anemia, n (%) 18 Destational anemia, n (%) 19 Destational anemia anemia, n (%) 19 Destational anemia an	(12.2) 4.3) (34.8) (60.9) (95.7) 4.3) .3 ± 5.3 6 ± 10.1	13 (7.4) 5 (2.9) 82 (46.9) 88 (50.3) 167 (95.4) 8 (4.6) 163.1 ± 4.8	0.108
Others* Delivery mode, n (%) Forceps delivery Spontaneous vaginal Delivery Caesarean section Conception method, n (%) Spontaneously conceived IVF-ET Maternal height, mean ± SD Destational weight before Delivery, mean ± SD Destational weight gain (kg), mean ± SD Destational weight gain (kg), mean ± SD Destational weight gain (kg), mean ± SD Destational hypertension, mean ± SD Destationa	(12.2) 4.3) (34.8) (60.9) (95.7) 4.3) .3 ± 5.3 6 ± 10.1	13 (7.4) 5 (2.9) 82 (46.9) 88 (50.3) 167 (95.4) 8 (4.6) 163.1 ± 4.8	0.928
Peleivery mode, n (%) Forceps delivery Spontaneous vaginal Auternal height, mean ± SD Forceptional weight gain (kg), me	4.3) (34.8) (60.9) (95.7) 4.3) .3 ± 5.3 6 ± 10.1	5 (2.9) 82 (46.9) 88 (50.3) 167 (95.4) 8 (4.6) 163.1 ± 4.8	0.928
Forceps delivery Spontaneous vaginal lelivery Caesarean section Conception method, n (%) Spontaneously conceived IVF-ET Maternal height, mean ± SD Maternal weight before lelivery, mean ± SD Sestational weight gain (kg), nean ± SD Pre-pregnancy BMI, 25 Pre-pregnancy BMI, 25 Preclampsia, n (%) 32 Preclampsia, n (%) 32 Pregnancy with uterine libroids, n (%) Pregnancy complicated (pypothyroidism, n (%) Pregnancy complicated (pypothyroidism, n (%) Maternal chronic disease (pefore pregnancy, n (%) Hypothyroidism (Connective tissue disease (hashimoto thyroiditis (hedication use in pregnancy, n (%) Levothyroxine (hedication (hedication) (hed	(34.8) (60.9) (95.7) 4.3) .3 ± 5.3 6 ± 10.1	82 (46.9) 88 (50.3) 167 (95.4) 8 (4.6) 163.1 ± 4.8	0.928
Spontaneous vaginal delivery Caesarean section Conception method, n (%) Spontaneously conceived IVF-ET Maternal height, mean ± SD Maternal weight before delivery, mean ± SD Gestational weight gain (kg), nean ± SD Pre-pregnancy BMI, 25 Pre-pregnancy BMI, 25 Pre-pregnancy BMI, 32 Preclampsia, n (%) 32 Prestational hypertension, 9 (%) Gestational anemia, n (%) 32 Pregnancy with uterine dibroids, n (%) Pregnancy complicated (%) Prednisone (%) Levothyroidism (%) Levothyroxine (%) Levothyroxine (%) Levothyroxine (%) Levothyroxine (%) Levothyroxine (%) Prednisone (%) Connective § (%) Levothyroxine (%) Levothyroxin	(34.8) (60.9) (95.7) 4.3) .3 ± 5.3 6 ± 10.1	82 (46.9) 88 (50.3) 167 (95.4) 8 (4.6) 163.1 ± 4.8	
delivery Caesarean section Conception method, n (%) Spontaneously conceived IVF-ET Maternal height, mean \pm SD Maternal weight before delivery, mean \pm SD Gestational weight gain (kg), nean \pm SD Pre-pregnancy BMI, 25. Pre-pregnancy BMI, 25. Pre-clampsia, n (%) Gestational hypertension, 9 (%) Prescalampsia, n (%) Gestational anemia, n (%) Pregnancy with uterine dibroids, n (%) Pregnancy complicated (hypothyroidism, n (%) Pregnancy complicated (hypothyroidism, n (%) Maternal chronic disease (hashimoto thyroiditis) Connective tissue disease Hashimoto thyroiditis Others (hypothyroxine) Aspirin Labetalol Prednisone Others (hypothyroxine) Aspirin Labetalol Prednisone Others (hypothyroxine) A (hypothyroxi	(60.9) (95.7) 4.3) .3 ± 5.3 6 ± 10.1	88 (50.3) 167 (95.4) 8 (4.6) 163.1 ± 4.8	
Caesarean section Conception method, n (%) Spontaneously conceived IVF-ET Maternal height, mean \pm SD Maternal weight before Relivery, mean \pm SD Restational weight gain (kg), nean \pm SD Relivery mean \pm SD Reli	(95.7) 4.3) .3 ± 5.3 6 ± 10.1	167 (95.4) 8 (4.6) 163.1 ± 4.8	
Spontaneously conceived IVF-ET Maternal height, mean ± SD Maternal weight before Sestational weight gain (kg), mean ± SD Pre-pregnancy BMI, Pre-pregnancy BMI, Pre-clampsia, n (%) Sestational hypertension, Prestational anemia, n (%) Sestational anemia, n (%) Pregnancy with uterine Sibroids, n (%) Pregnancy complicated Sypothyroidism, n (%) Maternal chronic disease Prefore pregnancy, n (%) Hypothyroidism Connective tissue disease Hashimoto thyroiditis Others [†] Medication use in pregnancy, (%) Levothyroxine Aspirin Labetalol Prednisone Others [§] 2 ((95.7) 4.3) .3 ± 5.3 6 ± 10.1	167 (95.4) 8 (4.6) 163.1 ± 4.8	
Spontaneously conceived IVF-ET 5 (Maternal height, mean ± SD 16/1 Maternal weight before 16/1 Meternal weight before 16/1 Meternal weight gain (kg), 10. Mean ± SD 16/1 Meternal weight gain (kg), 10. Mean ± SD 16/1 Meternal solution (kg), 10. Meternal solution (kg), 10. Meternal solution (kg), 10. Meternal solution (kg), 10. Meternal chronic disease 16/1 Medication use in pregnancy, 16/1 Medication use in preg	4.3) .3 ± 5.3 6 ± 10.1	8 (4.6) 163.1 ± 4.8	
Spontaneously conceived IVF-ET 5 (Maternal height, mean ± SD 16/1 Maternal weight before 16/1 Meternal weight before 16/1 Meternal weight gain (kg), 10. Mean ± SD 16/1 Meternal weight gain (kg), 10. Mean ± SD 16/1 Meternal solution (kg), 10. Meternal solution (kg), 10. Meternal solution (kg), 10. Meternal solution (kg), 10. Meternal chronic disease 16/1 Medication use in pregnancy, 16/1 Medication use in preg	4.3) .3 ± 5.3 6 ± 10.1	8 (4.6) 163.1 ± 4.8	0.003
IVF-ET	4.3) .3 ± 5.3 6 ± 10.1	8 (4.6) 163.1 ± 4.8	0.003
Maternal height, mean ± SD Maternal weight before lelivery, mean ± SD Gestational weight gain (kg), nean ± SD Pre-pregnancy BMI, nean ± SD ROM, n (%) Precclampsia, n (%) Gestational hypertension, n (%) Gestational anemia, n (%) Gestational anemia, n (%) Pregnancy with uterine Pregnancy complicated	.3 ± 5.3 6 ± 10.1	163.1 ± 4.8	0.003
Maternal weight before felivery, mean ± SD festational weight gain (kg), finean ± SD fre-pregnancy BMI, fre-pregnancy it		70.1 ± 9.1	
delivery, mean ± SD destational weight gain (kg), nean ± SD dere-pregnancy BMI, 25. dere-pregnancy in (%) 27. dere-pregnancy in (%) 32. dere-pregnancy in (%) 32. deregnancy with uterine in dere-pregnancy complicated in (%) 26. deregnancy in (%) 26. deregnanc			0.0012
destational weight gain (kg), nean ± SD Pre-pregnancy BMI, 25. Pre-pregnancy in the second sec	0 . 45		
nean ± SD Pre-pregnancy BMI, 25. Preaclampsia, n (%) 27 Preeclampsia, n (%) 12 Prestational hypertension, 9 (Prestational anemia, n (%) 23 Pregnancy with uterine 16 Pregnancy complicated 6 (Prednisone 6 (Prednisone 7 (Pregnancy complicated 6 (Prednisone 7 (Pregnancy complicated 6 (Prednisone 7 (Pregnancy complicated 6 (Prednisone 7 (Pre	9 ± 4.5	11.6 ± 4.1	0.1867
Pre-pregnancy BMI, 25. Prenant ± SD PROM, n (%) 27 Preeclampsia, n (%) 12 Preeclampsia, n (%) 32 Preeclampsia, n (%) 32 Preeclampsia, n (%) 32 Preeclampsia, n (%) 32 Pregnancy with uterine 36 Pregnancy complicated 37 Pregnancy complicated 38 Pregnancy complicated 39 Pregnancy complicated 39 Pregnancy complicated 39 Predicated 30 Predication use in pregnancy, 30 Predication use in predication use in predication use in predication use	J _ 1.J	11.0 2 1.1	0.1007
nean ± SD PROM, n (%) 27 Preeclampsia, n (%) 12 Pregnancy with uterine 16 Pregnancy complicated 16 Pregnancy complicated 16 Pregnancy complicated 16 Prefore pregnancy, n (%) 16 Prepnancy complicated 17 Prefore pregnancy, n (%) 17 Prepnancy complicated 18 Prefore pregnancy, n (%) 18 Prefore pregnancy, n (%) 19 Predication use in pr	6 ± 3.3	26.3 ± 3.4	0.0551
PROM, <i>n</i> (%) 27 Preeclampsia, <i>n</i> (%) 12 Estational hypertension, 9 ((%) 32 Estational anemia, <i>n</i> (%) 23 Pregnancy with uterine 16 Eibroids, <i>n</i> (%) 26 Pregnancy complicated 6 (Pypothyroidism, <i>n</i> (%) 26 Estational anemia, <i>n</i> (%) 26 Estational anemia, <i>n</i> (%) 27 Eregnancy complicated 6 (Pypothyroidism, <i>n</i> (%) 26 Estational chronic disease 27 Eregnancy complicated 6 (Pypothyroidism, <i>n</i> (%) 26 Estational chronic disease 27 Eregnancy complicated 6 (Pypothyroidism, <i>n</i> (%) 26 Estational chronic disease 29 Eregnancy complicated 6 (Pypothyroidism, <i>n</i> (%) 20 Expothyroidism, <i>n</i> (%) 20 Eventually 2	0 ± 5.5	20.5 ± 5.4	0.0551
Preeclampsia, n (%) Gestational hypertension, (%) Gestational hypertension, (%) Gestational anemia, n (%) Pregnancy with uterine Gibroids, n (%) Pregnancy complicated (pypothyroidism, n (%) GES (+), n (%) Auternal chronic disease Gefore pregnancy, n (%) Hypothyroidism (Connective tissue disease Hashimoto thyroiditis Others† Adedication use in pregnancy, (%) Levothyroxine Aspirin Labetalol Prednisone Others§ 20	(23.5)	54 (30.9)	0.171
Sestational hypertension, 9 (10%) SDM, n (%) SESTATIONAL APPRINTENSION, n (%) Addernal chronic disease SESTATIONAL APPRINTENSION, n (%) Hypothyroidism 6 (Connective tissue disease 6 (Hashimoto thyroiditis 1 (%) Others† 6 (Medication use in pregnancy, n (%) Levothyroxine 8 (Aspirin 5 (Labetalol 2 (Prednisone 4 (Others§ 2 2	(23.3)	9 (5.1)	0.089
f (%) GDM, n (%) Gestational anemia, n (%) Gregnancy with uterine Gibroids, n (%) Gregnancy complicated Greg		5 (2.9)	0.053
abom, n (%) assestational anemia, n (%) bregnancy complicated asporthyroidism, n (%) assestational chronic disease assestational anemia, n (%) assestational anemia	7.0)	3 (2.9)	0.033
Sestational anemia, n (%) Pregnancy with uterine Sibroids, n (%) Pregnancy complicated Siprothyroidism, n (%) Adaternal chronic disease Pefore pregnancy, n (%) Hypothyroidism Connective tissue disease Hashimoto thyroiditis Others† Aedication use in pregnancy, n (%) Levothyroxine Aspirin Labetalol Prednisone Others§ 20	(27.0)	16 (26 2)	0.772
regnancy with uterine fibroids, n (%) regnancy complicated regnancy complicated fibroids, n (%) regnancy complicated fibroids, n (%) regnancy complicated fibroids, n (%) fibr	(27.8)	46 (26.3)	0.772 0.564
ibroids, n (%) Pregnancy complicated Pregnancy complete c	(20.0)	40 (22.9)	
hypothyroidism, n (%) has $(3, 1)$ (%) has $(3, 1)$ (%) has $(3, 1)$ (%) hypothyroidism hypothyroidism has $(3, 1)$ (%) has himoto thyroiditis has himoto thyroiditis has himoto hyroiditis has him	(13.9)	20 (11.4)	0.53
Adetrial chronic disease before pregnancy, n (%) Hypothyroidism Connective tissue disease Hashimoto thyroiditis Others† 6 (Medication use in pregnancy, 1 (%) Levothyroxine Aspirin Labetalol Prednisone Others§ 2 (5.2)	13 (7.4)	0.457
Maternal chronic disease sefore pregnancy, n (%) Hypothyroidism 6 (Connective tissue disease 6 (Hashimoto thyroiditis 1 (Medication use in pregnancy, 20 (%) Levothyroxine 8 (Aspirin 5 (Labetalol 2 (Prednisone 4 (Others§ 2 (Medication) 2 (Medicati			
refore pregnancy, n (%) Hypothyroidism Connective tissue disease Hashimoto thyroiditis Others [†] Medication use in pregnancy, (%) Levothyroxine Aspirin Solution is a specific consistency of the specific consistency	1.7)	5 (2.9)	0.707
Hypothyroidism 6 (Connective tissue disease 6 (Hashimoto thyroiditis 1 (Others† 6 (Medication use in pregnancy, 20 (%) Levothyroxine 8 (Aspirin 5 (Labetalol 2 (Prednisone 4 (Others§ 2 (
Connective tissue disease 6 (Hashimoto thyroiditis 1 (i Others† 6 (Medication use in pregnancy, 20 (%) Levothyroxine 8 (Aspirin 5 (Labetalol 2 (Prednisone 4 (Others§ 2 (
Hashimoto thyroiditis 1 (1) Others† 6 (Medication use in pregnancy, 20 (%) Levothyroxine 8 (Aspirin 5 (Labetalol 2 (Prednisone 4 (Others§ 20		9 (5.1)	0.978
Others [†] 6 (Medication use in pregnancy, 20 (%) Levothyroxine 8 (Aspirin 5 (Labetalol 2 (Prednisone 4 (Others [§] 2 (5.2)	1 (0.6)	0.017
Others [†] 6 (Medication use in pregnancy, 20 (%) Levothyroxine 8 (Aspirin 5 (Labetalol 2 (Prednisone 4 (Others [§] 2 (5.2) 5.2)	4 (2.3)	0.651
Medication use in pregnancy, 20 (%) Levothyroxine 8 (Aspirin 5 (Labetalol 2 (Prednisone 4 (Others§ 2 (5.2)	11 (6.3)	0.705
(%) Levothyroxine 8 (Aspirin 5 (Labetalol 2 (Prednisone 4 (Others§ 2 (5.2)).9)	31 (17.7)	0.944
Levothyroxine 8 (Aspirin 5 (Labetalol 2 (Prednisone 4 (Others§ 2 (5.2)).9) 5.2)		
Aspirin 5 (Labetalol 2 (Prednisone 4 (Others [§] 2 (5.2)).9)		0.332
Labetalol 2 (Prednisone 4 (Others [§] 2 (5.2)).9) 5.2) (17.4)		0.491
Prednisone 4 (Others [§] 2 (5.2) (0.9) (5.2) (17.4) (17.0)	18 (10.3)	0.485
Others [§] 2 (5.2) 5.2) 5.2) (17.4) 7.0) 4.3)	18 (10.3) 4 (2.3)	
	5.2) 5.2) 5.2) (17.4) 7.0) 4.3)	18 (10.3) 4 (2.3) 6 (3.4)	0.083
	5.2) 5.2) 5.2) (17.4) 7.0) 4.3) 1.7)	18 (10.3) 4 (2.3) 6 (3.4) 1 (0.6)	0.083 0.707
haracteristics	5.2) 5.2) 5.2) (17.4) 7.0) 4.3)	18 (10.3) 4 (2.3) 6 (3.4)	0.083 0.707
	5.2) 5.2) 5.2) (17.4) 7.0) 4.3) 1.7)	18 (10.3) 4 (2.3) 6 (3.4) 1 (0.6)	
	5.2) 5.2) 5.2) (17.4) 7.0) 4.3) 1.7) 3.5)	18 (10.3) 4 (2.3) 6 (3.4) 1 (0.6) 5 (2.9)	0.707
luid, n (%)	5.2) 0.9) 5.2) (17.4) 7.0) 4.3) 1.7) 3.5) 1.7)	18 (10.3) 4 (2.3) 6 (3.4) 1 (0.6) 5 (2.9)	0.707
Jmbilical cord	5.2) 5.2) 5.2) (17.4) 7.0) 4.3) 1.7) 3.5)	18 (10.3) 4 (2.3) 6 (3.4) 1 (0.6) 5 (2.9)	0.707
haracteristics	5.2) 0.9) 5.2) (17.4) 7.0) 4.3) 1.7) 3.5) 1.7)	18 (10.3) 4 (2.3) 6 (3.4) 1 (0.6) 5 (2.9)	0.707

(Continued)

Table 2: Continued

Variables	TLBW group (n = 115)	TNBW group (<i>n</i> = 175)	<i>P</i> value
Umbilical cord around the neck, <i>n</i> (%)	35 (30.4)	52 (29.7)	0.896
Umbilical cord twist, n (%)	26 (22.6)	14 (8.0)	<0.001
Umbilical cord prolapse, <i>n</i> (%)	4 (3.5)	2 (1.1)	0.219
True umbilical cord knot, n (%)	2 (1.7)	1 (0.6)	0.565
Placenta characteristics			
Velamentous placenta, n (%)	3 (2.6)	1 (0.6)	0.304
Battledore placenta, n (%)	4 (3.5)	7 (4.0)	1
Placental abruption, n (%)	2 (1.7)	2 (1.1)	0.65
Placenta adhesion, n (%)	2 (1.7)	4 (2.3)	1
Low-lying placenta, n (%)	7 (6.1)	17 (9.7)	0.346
Placenta previa, n (%)	1 (0.9)	3 (1.7)	1

^{*}Includes Hui, Manchu, Mongolians, and other ethnic minorities. [†]Includes hyperthyroidism, asthma, nephritis, epilepsy, and others. §Includes insulin, inhaled corticosteroids, and others. IVF-ET, in vitro fertilization and embryo transfer; BMI, body mass index; PROM, premature rupture of membranes; GDM, gestational diabetes

mellitus; GBS, group B streptococcus.

The mean, interquartile range values of the placental morphology measurements are shown in Table S1. The placenta weight (479.0 \pm 80.1 vs 597.1 \pm 83.1 cm), length

 $(16.3 \pm 2.1 \text{ vs } 18.8 \pm 2.0 \text{ cm})$, width $(14.3 \pm 2.1 \text{ vs } 16.9 \text{ vs } 16.9 \text{ vs } 16.9 \text{ vs }$ 2.0 cm), and thickness (2.3 \pm 0.5 vs 2.4 \pm 0.4 cm) in the TLBW group were much lower than those in the control group (all P < 0.001).

3.2 Placental weight and width are associated with TLBW

Univariate predictors of TLBW included placental weight, length, width, thickness, volume, surface area, and specific surface area. Among these, smaller placental weight, length, width, thickness, volume, and surface area were identified as associated with TLBW, while smaller specific surface area was found to be associated with a lower risk of TLBW (Figure 2). Placental weight (aOR for per 10 g increase: 0.89; 95% CI: 0.84-0.94) and width (aOR for per 1 cm increase: 0.69; 95% CI: 0.54-0.88) remained to be independent predictors even after controlling for relevant confounders in the final multivariate regression model (Figure 2).

The results were consistent when these morphometric parameters were analyzed as categorical variables (Figure 3). We observed that the odds of TLBW were higher when placental weight was below the 50th percentile (aOR: 5.08, 95% CI: 2.59–9.95) in the multivariate model. Similarly,




Figure 2: Forest plots of univariate and multivariate logistic regression analysis results of continuous placental morphology measurements.

placental width below the 50th percentile was significantly associated with an increased risk of TLBW (aOR: 6.57, 95% CI: 2.73–15.82).

A nomogram was developed to predict the probability of TLBW based on the two independent parameters of placental weight and width (Figure 4). Each predictor is given a score on the point scale axis based on its value, and the total score is calculated by adding each individual score. The predicted TLBW risk can be determined by projecting the total score line straight to the probability scale line at the bottom. The calibration plots indicated a high level of agreement between the prediction model and the actual results (Figure 5). To further evaluate the performance of the prediction model, a receiver operating characteristic (ROC) curve was plotted (Figure 6). The area under the curve was 0.905 (95% CI: 0.87–0.939), suggesting that the model has good discriminatory ability.

4 Discussion

The size, shape, and structure of the placenta are crucial factors for healthy fetal development. There is ongoing research and debate about the relationship between

placental morphological changes and adverse pregnancy outcomes. Our case-control matched design study included around 300 term singleton livebirths delivered in a tertiary general hospital. To our knowledge, this study is one of the largest sample size studies conducted to date, and has employed statistical methods such as univariate and multivariate logistic regression to identify predictors of TLBW. We observed that placental weight and width were associated with increased risk of TLBW. The risk of TLBW decreased by 11 and 31% for every 10 g increase in placental weight and 1cm increase in width diameter, respectively. Neonates with a placental weight less than 550 g had a 5.08-fold higher risk of TLBW compared to those with a placental weight greater than 550 g. Placental width diameter ≤16 cm showed a 6.57-fold of TLBW compared with those with longer width (more than 16 cm).

In the present study, we identified significant differences in placental weight between the TLBW and control groups. Similar findings were reported in previous studies, including one by Zheng et al., which found a significant difference in placental weight between TLBW and TNBW infants, with the TLBW group having a significantly lower placental weight $(492.8 \pm 38.5 g)$ compared to the TNBW group $(701.2 \pm 106.7 g)$ [26]. In addition, a study in India





Figure 3: Forest plots of univariate and multivariate logistic regression analysis results of categorical placental morphology measurements.






Figure 4: Nomogram for TLBW.




Figure 5: Calibration curves for the nomogram.

B — Jing Liu et al. DE GRUYTER




Figure 6: ROC curve of the nomogram.

demonstrated that preterm LBW had lower mean placental weight than TLBW infants (410.2 g \pm 101.3 vs 469.1 \pm 55.8 g) [27]. Similar results were found in SGA and neonates with IUGR. Biswas and Ghosh reported a mean placental weight of 333.32 \pm 75.59 g for the IUGR group and 416.77 \pm 63.03 g for the control group [18]. Chisholm and Folkins observed that the mean placental weight of term SGA group was 351.85 \pm 139.28 g and that of AGA group was 445.90 \pm 86.33 g [21].

More importantly, our logistic regression analysis further confirmed that placental weight was an independent predictive factor of TLBW. There was a significant relationship between placental weight and TLBW whether treated as a continuous or categorical variable. Many studies have shown that there is a positive correlation between placental weight and birth weight. For example, the prospective study conducted in Mexico found that for each 1g increase in placental weight, there was a corresponding increase of approximately 1.98 g in birth weight among term newborns [28]. Similarly, placenta weight percentile curves according to gestational weight for singleton and twins deliveries in Canadian population fit by appearance positive linear relations [29]. These findings suggest that placental weight may play an important role in fetal growth and development, as well as serve as an indicator of efficacy in nutrient and oxygen transport. Additionally, the ratio of birth weight to placental weight has been proposed as a marker of placental efficiency [30–32].

Decreased placental width diameter was another predictor of TLBW in this study. Although length, thickness, volume, surface area, and specific surface area were significant on univariate analysis, they failed to confirm the multivariate importance. Haeussner et al. found that the shape of the placental disc converges toward a roundish, but not precisely circular [33]. Lower birth weight was observed in non-round/oval placentas [34]. The difference in length and width reflects the degree of ovality of the placenta. In this study, however, the difference in diameters between the two groups was not significant. We speculate that differences in placental shape may represent an adaptation to the unique environmental conditions experienced by each fetus, which may differ from placental weight.

Indeed, in addition to placental weight and gross morphological parameters, placental parameters measured by ultrasound, such as placental volume, thickness, and vascularity, have been shown to correlate with fetal growth. A prospective study of 619 Chinese women with singleton pregnancy revealed that placental volume in early pregnancy was an independent predictor of SGA [35]. Studies have demonstrate that placental evaluation using threedimensional ultrasonographic placental measurements at 11–14 weeks of gestation can significantly improve the early prediction of SGA [36,37]. However, there is currently no standardized method for assessing antepartum placental growth during pregnancy. Additionally, the additional time required for 3D measurements compared to 2D measurements, the lack of machines capable of multiplanar reconstruction, and the lack of a universal reference range for placental measurements are some of the limitations that must be addressed for ultrasound measurement of the placenta to become a standard diagnostic tool.

Overall, this study has several strengths, including a sufficient sample size and the use of reproducible and reliable measurement indicators for the general parameters of the placenta. Furthermore, we identified two important predictors (placental weight and placental width) that are important parameters for prediction of TLBW. We also controlled for confounding factors such as gestational age, mother's height, and weight before delivery, which strengthens the validity of our results. However, there were several limitations. First, we only measured placental morphology at delivery, and future studies that include parameters related to placental structure and function during pregnancy may offer more valuable insights. Second, this study was conducted at a single center, which may limit the generalizability of our results. Multicentric validation could enhance the external applicability of our findings. Third, although matching was performed on key variables, other important determinants of fetal growth were not accounted for a priori, and residual confounding remains possible despite post hoc adjustment.

5 Conclusions

In conclusion, it appears that the placentas in the TLBW group were generally smaller than those in the TNBW group, as evidenced by differences in weight, length, width, thickness, volume, and surface area. We identified placental weight and width as independent predictors of TLBW, indicating that both placental weight and size or shape may be linked to fetal growth. However, as this study is observational, further research is needed to better understand the underlying mechanisms and to explore effective strategies for monitoring placental health during pregnancy. Future studies should also include antepartum imaging or biomarkers to enhance prenatal prediction and assess the clinical applicability of these findings.

Acknowledgments: The authors thank all the participants in this study.

Funding information: This work was funded by National High Level Hospital Clinical Research Funding (2022-NHLHCRF-LX-01-0301) and the Clinical research project of Beijing research ward construction (2022-YJXBF-04-01-03).

Author contributions: Conception and design: L.J. and Z.Q.; administrative support: Z.Q.; provision of study materials or patients: L.H.X. and Y.F.; collection and assembly of data: L.D. and C.Y.M.; data analysis and interpretation: L.J. and S.Q.; manuscript writing: L.J. and Z.Q.; final approval of manuscript: all authors.

Conflict of interest: The authors state no conflict of interest.

Data availability statement: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

- Blencowe H, Krasevec J, de Onis M, Black RE, An X, Stevens GA, et al. National, regional, and worldwide estimates of low birthweight in 2015, with trends from 2000: a systematic analysis. Lancet Glob Health. 2019;7(7):e849-60.
- Villar J, Belizan JM. The relative contribution of prematurity and fetal growth retardation to low birth weight in developing and developed societies. Am J Obstet Gynecol. 1982;143(7):793-8.
- Williams RL, Creasy RK, Cunningham GC, Hawes WE, Norris FD, Tashiro M. Fetal growth and perinatal viability in California. Obstet Gynecol. 1982;59(5):624-32.

- Barker DJ, Gelow J, Thornburg K, Osmond C, Kajantie E, Eriksson JG. The early origins of chronic heart failure: impaired placental growth and initiation of insulin resistance in childhood. Eur J Heart Fail. 2010;12(8):819-25.
- Gjerde A, Reisaeter AV, Skrunes R, Marti HP, Vikse BE. Intrauterine growth restriction and risk of diverse forms of kidney disease during the first 50 years of life. Clin J Am Soc Nephrol. 2020;15(10):1413-23.
- Arumugasaamy N. Rock KD. Kuo CY. Bale TL. Fisher IP. [6] Microphysiological systems of the placental barrier. Adv Drug Deliv Rev. 2020;161-162:161-75.
- Maltepe E, Fisher SJ. Placenta: the forgotten organ. Annu Rev Cell Dev Biol. 2015;31:523-52.
- Fowden AL, Ward JW, Wooding FP, Forhead AJ, Constancia M. Programming placental nutrient transport capacity. J Physiol. 2006;572(Pt 1):5-15.
- Brett KE, Ferraro ZM, Yockell-Lelievre J, Gruslin A, Adamo KB. [9] Maternal-fetal nutrient transport in pregnancy pathologies: the role of the placenta. Int J Mol Sci. 2014;15(9):16153-85.
- [10] Hay Jr WW. Placental transport of nutrients to the fetus. Horm Res. 1994;42(4-5):215-22.
- Aiko Y, Askew DJ, Aramaki S, Myoga M, Tomonaga C, Hachisuga T, et al. Differential levels of amino acid transporters system L and ASCT2, and the mTOR protein in placenta of preeclampsia and IUGR. BMC Pregnancy Childbirth. 2014;14:181.
- Green ES, Arck PC. Pathogenesis of preterm birth: bidirectional inflammation in mother and fetus. Semin Immunopathol. 2020;42(4):413-29.
- Kingdom JC, Audette MC, Hobson SR, Windrim RC, Morgen E. [13] A placenta clinic approach to the diagnosis and management of fetal growth restriction. Am J Obstet Gynecol. 2018;218(2):S803-17.
- Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol. 2019;15(5):275-89.
- [15] Ohqiya Y, Nobusawa H, Seino N, Miyaqami O, Yaqi N, Hiroto S, et al. MR imaging of fetuses to evaluate placental insufficiency. Magn Reson Med Sci. 2016;15(2):212-9.
- Salafia CM, Yampolsky M, Misra DP, Shlakhter O, Haas D, Eucker B, et al. Placental surface shape, function, and effects of maternal and fetal vascular pathology. Placenta. 2010;31(11):958-62.
- [17] Salafia CM, Misra DP, Yampolsky M, Charles AK, Miller RK. Allometric metabolic scaling and fetal and placental weight. Placenta. 2009;30(4):355-60.
- [18] Biswas S, Ghosh SK. Gross morphological changes of placentas associated with intrauterine growth restriction of fetuses: a case control study. Early Hum Dev. 2008;84(6):357-62.
- [19] Damodaram M, Story L, Eixarch E, Patel A, McGuinness A, Allsop J, et al. Placental MRI in intrauterine fetal growth restriction. Placenta. 2010;31(6):491-8.
- [20] Liu HJ, Liu PC, Hua J, Zhao Y, Cao J. Placental weight and size in relation to fetal growth restriction: a case-control study. J Matern Fetal Neonatal Med. 2021;34(9):1356-60.
- [21] Chisholm KM, Folkins AK. Placental and clinical characteristics of term small-for-gestational-age neonates: a case-control study. Pediatr Dev Pathol. 2016;19(1):37-46.
- [22] Zhu YD, Gao H, Huang K, Zhang YW, Cai XX, Yao HY, et al. Prenatal phthalate exposure and placental size and shape at birth: a birth cohort study. Env Res. 2018;160:239-46.
- [23] Holroyd CR, Osmond C, Barker DJ, Ring SM, Lawlor DA, Tobias JH, et al. Placental size is associated differentially with postnatal bone size and density. J Bone Min Res. 2016;31(10):1855-64.

DE GRUYTER

- [24] Wang LJ, Fan DZ, Guo HX, Chen BS, Liu ZP. Weight gain during pregnancy and placenta morphology: a prospective cohort study. Eur Rev Med Pharmacol Sci. 2022;26(6):1978–83.
- [25] Tian FY, Wang XM, Xie C, Zhao B, Niu Z, Fan L, et al. Placental surface area mediates the association between FGFR2 methylation in placenta and full-term low birth weight in girls. Clin Epigenet. 2018:10:39.
- [26] Zheng J, Xiao X, Zhang Q, Mao L, Yu M, Xu J. The placental microbiome varies in association with low birth weight in full-term neonates. Nutrients. 2015;7(8):6924–37.
- [27] Jaya DS, Kumar NS, Bai LS. Anthropometric indices, cord length and placental weight in newborns. Indian Pediatr. 1995;32(11):1183–8.
- [28] Sanin LH, Lopez SR, Olivares ET, Terrazas MC, Silva MA, Carrillo ML. Relation between birth weight and placenta weight. Biol Neonate. 2001;80(2):113–7.
- [29] Almog B, Shehata F, Aljabri S, Levin I, Shalom-Paz E, Shrim A. Placenta weight percentile curves for singleton and twins deliveries. Placenta. 2011;32(1):58–62.
- [30] Salavati N, Gordijn SJ, Sovio U, Zill EHR, Gebril A, Charnock-Jones DS, et al. Birth weight to placenta weight ratio and its relationship to ultrasonic measurements, maternal and neonatal morbidity: a prospective cohort study of nulliparous women. Placenta. 2018;63:45–52.
- [31] Hayward CE, Lean S, Sibley CP, Jones RL, Wareing M, Greenwood SL, et al. Placental adaptation: what can we

- learn from birthweight: placental weight ratio? Front Physiol. 2016:7:28
- [32] Ganer Herman H, Miremberg H, Schreiber L, Bar J, Kovo M. The association between disproportionate birth weight to placental weight ratio, clinical outcome, and placental histopathological lesions. Fetal Diagn Ther. 2017;41(4):300–6.
- [33] Haeussner E, Schmitz C, von Koch F, Frank HG. Birth weight correlates with size but not shape of the normal human placenta. Placenta. 2013;34(7):574–82.
- [34] Yampolsky M, Salafia CM, Shlakhter O, Haas D, Eucker B, Thorp J. Modeling the variability of shapes of a human placenta. Placenta. 2008;29(9):790–7.
- [35] Law LW, Leung TY, Sahota DS, Chan LW, Fung TY, Lau TK. Which ultrasound or biochemical markers are independent predictors of small-for-gestational age? Ultrasound Obstet Gynecol. 2009;34(3):283–7.
- [36] Schwartz N, Sammel MD, Leite R, Parry S. First-trimester placental ultrasound and maternal serum markers as predictors of small-forgestational-age infants. Am J Obstet Gynecol. 2014;211(3):253.e251–8.
- [37] Collins SL, Stevenson GN, Noble JA, Impey L. Rapid calculation of standardized placental volume at 11 to 13 weeks and the prediction of small for gestational age babies. Ultrasound Med Biol. 2013;39(2):253–60.